## Insulin-mediated sympathetic stimulation: role in the p hypertension (or, how insulin affects blood pressure, an

Journal of Hypertension 19, 523-528 DOI: 10.1097/00004872-200103001-00001

**Citation Report** 

#	Article	IF	CITATIONS
1	Obesity and hypertension: cause or consequence?. Journal of Hypertension, 2001, 19, 2125-2126.	0.3	10
2	Chronic Cardiovascular and Renal Actions of Leptin. Hypertension, 2002, 39, 496-501.	1.3	270
3	Obesity, hypertension and the sympathetic nervous system. Journal of Hypertension, 2002, 20, 835-837.	0.3	8
4	Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Current Opinion in Cardiology, 2002, 17, 355-359.	0.8	34
5	Insulin resistance and hypertension: lessons learned from studies in children. Journal of Hypertension, 2002, 20, 383-385.	0.3	1
6	Obesity-related hypertension: relevance of vascular responses to mental stress. Journal of Hypertension, 2002, 20, 1277-1278.	0.3	5
7	Obesity-related hypertension: Role of the sympathetic nervous system, insulin, and leptin. Current Hypertension Reports, 2002, 4, 112-118.	1.5	38
8	Pathways from weight fluctuations to metabolic diseases: focus on maladaptive thermogenesis during catch-up fat. International Journal of Obesity, 2002, 26, S46-S57.	1.6	102
9	Eradication of Helicobacter pylori Infection Improves Blood Pressure Values in Patients Affected by Hypertension. Helicobacter, 2003, 8, 585-589.	1.6	58
10	Justification for antioxidant preconditioning (or how to protect insulin-mediated actions under) Tj ETQq1 1 0.784	314 rgBT 0.5	/Oyerlock 10
11	Diet-induced obesity and cardiovascular regulation in C57BL/6J mice. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 769-778.	0.9	62
12	Plasma Leptin and Blood Pressure in Men: Graded Association Independent of Body Mass and Fat Pattern. Obesity, 2003, 11, 160-166.	4.0	75
13	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. American Journal of Cardiology, 2003, 92, 337-341.	0.7	31
14	Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation. Hypertension, 2003, 42, 474-480.	1.3	458
15	Visceral Adiposity and the Prevalence of Hypertension in Japanese Americans. Circulation, 2003, 108, 1718-1723.	1.6	121
16	Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients. Hypertension, 2003, 42, 873-877.	1.3	95
17	Sympathetic control of the circulation in hypertension: lessons from autonomic disorders. Current Opinion in Nephrology and Hypertension, 2003, 12, 175-180.	1.0	31
18	Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals. Journal of Hypertension, 2003, 21, 1761-1769.	0.3	202

ATION REDO

#	Article	IF	Citations
19	Chronic cardiovascular and renal actions of leptin during hyperinsulinemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2003, 284, R1037-R1042.	0.9	22
20	Role of Melanocortin-4 Receptors in Mediating Renal Sympathoactivation to Leptin and Insulin. Journal of Neuroscience, 2003, 23, 5998-6004.	1.7	169
21	Obésité humaine et système nerveux sympathique. Oleagineux Corps Gras Lipides, 2003, 10, 124-130.	0.2	0
22	Dbh(-/-) mice are hypotensive, have altered circadian rhythms, and have abnormal responses to dieting and stress. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R108-R113.	0.9	60
23	Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome. Circulation, 2004, 110, 1507-1512.	1.6	176
24	Relationship between Body Mass Index and Anti-Hypertensive Efficacy of Doxazosin According to a Survey of Japanese Patients. Journal of International Medical Research, 2004, 32, 176-184.	0.4	2
25	Chronic Sympathetic Activation: Consequence and Cause of Age-Associated Obesity?. Diabetes, 2004, 53, 276-284.	0.3	140
26	Vascular Response to Angiotensin II in Upper Body Obesity. Hypertension, 2004, 44, 435-441.	1.3	30
27	Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension. Journal of Hypertension, 2004, 22, 1671-1672.	0.3	5
28	Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1895-H1905.	1.5	113
29	Substrate cycling between de novo lipogenesis and lipid oxidation: a thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity. International Journal of Obesity, 2004, 28, S29-S37.	1.6	73
30	Pathogenesis of Hypertension in African Americans. Congestive Heart Failure, 2004, 10, 24-29.	2.0	39
31	Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutrition and Metabolism, 2004, 1, 12.	1.3	224
32	What is the Relationship Between Exercise and Metabolic Abnormalities?. Sports Medicine, 2004, 34, 371-418.	3.1	249
33	Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. Medical Hypotheses, 2004, 62, 830-838.	0.8	30
34	AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase. Medical Hypotheses, 2004, 63, 328-333.	0.8	20
35	Correlates of carotid artery stiffness in young adults: The Bogalusa Heart Study. Atherosclerosis, 2004, 176, 157-164.	0.4	94
36	Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension, 2004, 22, 2363-2369.	0.3	271

#	Article	IF	CITATIONS
37	Elevated sympathetic nerve activity. Journal of Hypertension, 2004, 22, 1087-1089.	0.3	6
38	Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. Journal of Hypertension, 2004, 22, 1999-2006.	0.3	31
39	Visceral Adiposity Is an Independent Predictor of Incident Hypertension in Japanese Americans. Annals of Internal Medicine, 2004, 140, 992.	2.0	234
40	Cardiovascular stress responsivity, body mass and abdominal adiposity. International Journal of Obesity, 2005, 29, 1329-1337.	1.6	88
41	Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia, 2005, 48, 1359-1365.	2.9	259
42	Insulin resistance and the metabolic syndrome. Diabetologia, 2005, 48, 1244-1246.	2.9	73
43	Melanocortin-4 Receptor–Deficient Mice Are Not Hypertensive or Salt-Sensitive Despite Obesity, Hyperinsulinemia, and Hyperleptinemia. Hypertension, 2005, 46, 326-332.	1.3	132
44	Dietary Fiber and Blood Pressure. Archives of Internal Medicine, 2005, 165, 150.	4.3	349
45	Obstructive Sleep Apnea–Dependent and –Independent Adrenergic Activation in Obesity. Hypertension, 2005, 46, 321-325.	1.3	196
46	Metabolic Syndrome: Is There a Pathophysiological Common Denominator?. , 2005, 94, 75-83.		7
47	Influence of metabolic syndrome on arterial stiffness and its age-related change in young adults: the Bogalusa Heart Study. Atherosclerosis, 2005, 180, 349-354.	0.4	84
48	Insulin Signaling in the Central Nervous System: A Critical Role in Metabolic Homeostasis and Disease From C. elegans to Humans. Diabetes, 2005, 54, 1264-1276.	0.3	312
49	Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 441-449.	1.1	58
50	Distribution and Correlates of Arterial Compliance Measures in Asymptomatic Young Adults: The Bogalusa Heart Study. American Journal of Hypertension, 2005, 18, 684-691.	1.0	35
51	ls Low-Risk Hypertension Fact or Fiction?Cardiovascular Risk Profile in the TROPHY Study. American Journal of Hypertension, 2005, 18, 980-985.	1.0	29
52	High-fat meal impairs vascular compliance in a subgroup of young healthy subjects. Metabolism: Clinical and Experimental, 2005, 54, 1337-1344.	1.5	36
53	Pathophysiology of Insulin Action in Humans. , 2005, , 179-197.		2
54	The Effect of Moxonidine on Endothelial Dysfunction in Metabolic Syndrome. American Journal of Cardiovascular Drugs, 2006, 6, 343-348.	1.0	37

#	Article	IF	CITATIONS
55	Correlates of vascular structure and function measures in asymptomatic young adults: The Bogalusa Heart Study. Atherosclerosis, 2006, 189, 1-7.	0.4	76
57	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
58	Actions of Peroxisome Proliferator–Activated Receptors–γ Agonists Explaining a Possible Blood Pressure–Lowering Effect. American Journal of Hypertension, 2006, 19, 646-653.	1.0	72
59	Insulin resistance is associated with hypertensive response to exercise in non-diabetic hypertensive patients. Diabetes Research and Clinical Practice, 2006, 73, 65-69.	1.1	15
60	Effects of chili consumption on postprandial glucose, insulin, and energy metabolism. American Journal of Clinical Nutrition, 2006, 84, 63-69.	2.2	119
61	Chronic central nervous system hyperinsulinemia and regulation of arterial pressure and food intake. Journal of Hypertension, 2006, 24, 1391-1395.	0.3	16
62	A TELEOLOGICAL VIEW OF OBESITY, DIABETES AND HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 863-867.	0.9	19
63	Selective imidazoline agonist moxonidine in obese hypertensive patients. International Journal of Clinical Practice, 2006, 60, 621-629.	0.8	32
64	Regional fat localizations and racial/ethnic variations in odds of hypertension in at-risk American adults. Journal of Human Hypertension, 2006, 20, 362-371.	1.0	13
65	Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Prostate Reports, 2006, 4, 127-131.	0.1	6
66	Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Urology Reports, 2006, 7, 288-292.	1.0	90
67	Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. Journal of Hypertension, 2006, 24, 47-49.	0.3	24
68	Physical Activity, Insulin Sensitivity, and Hypertension among US Adults: Findings from the Insulin Resistance Atherosclerosis Study. American Journal of Epidemiology, 2006, 163, 921-928.	1.6	17
69	C-Reactive Protein Is an Intermediate Step Between Obesity and Hypertension. Archives of Internal Medicine, 2006, 166, 1526.	4.3	1
70	Does microvascular dysfunction link obesity with insulin resistance and hypertension?. Expert Review of Endocrinology and Metabolism, 2006, 1, 181-187.	1.2	1
71	The effects of thiazolidinediones on blood pressure levels – A systematic review. Blood Pressure, 2006, 15, 135-150.	0.7	62
72	Autonomic Contribution to Blood Pressure and Metabolism in Obesity. Hypertension, 2007, 49, 27-33.	1.3	128
73	Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1590-E1598.	1.8	82

#	Article	IF	CITATIONS
74	Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R962-R970.	0.9	42
75	The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets, 2007, 11, 191-205.	1.5	24
76	The Antinatriuretic Effect of Insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance?. American Journal of Nephrology, 2007, 27, 44-54.	1.4	70
77	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
78	Modest weight gain is associated with sympathetic neural activation in nonobese humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R1834-R1838.	0.9	71
79	The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension, 2007, 25, 909-920.	0.3	318
80	Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. Journal of Hypertension, 2007, 25, 1411-1419.	0.3	108
81	Abdominal Obesity: Role in the Pathophysiology of Metabolic Disease and Cardiovascular Risk. American Journal of Medicine, 2007, 120, S3-S8.	0.6	222
82	Neuroprotective potential of the Bahadori leanness program: A "mini-fast with exercise―strategy. Medical Hypotheses, 2007, 68, 935-940.	0.8	4
83	High fructose diet increases anterior hypothalamic alpha 2-adrenoceptors responsiveness. Neuroscience Letters, 2007, 423, 128-132.	1.0	8
84	Blood pressure at rest, during 24 h monitoring and in response to sympathetic stimulation in hypertensive patients with metabolic syndrome. International Journal of Cardiology, 2007, 117, 312-316.	0.8	11
85	GuÃas de práctica clÃnica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Espanola De Cardiologia, 2007, 60, 525.e1-525.e64.	0.6	13
86	Resolution of Bariatric Comorbidities: Hypertension. , 2007, , 371-376.		0
87	Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovascular Diabetology, 2007, 6, 26.	2.7	22
89	The Impact of the Components of Metabolic Syndrome on Heart Rate Variability: Using the NCEPâ€ATP III and IDF Definitions. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 584-591.	0.5	61
90	The Metabolic Syndrome. Endocrine Reviews, 2008, 29, 777-822.	8.9	1,513
92	Body Fat Distribution and Cardiovascular Risk. Archives of Internal Medicine, 2008, 168, 1607.	4.3	10
93	Pathophysiology of Primary Hypertension. , 2008, , 794-895.		3

#	Article	IF	CITATIONS
94	Insulin in the Brain Increases Gain of Baroreflex Control of Heart Rate and Lumbar Sympathetic Nerve Activity. Hypertension, 2008, 51, 514-520.	1.3	49
95	Pleiotropic effects of thiazolidinediones. Expert Opinion on Pharmacotherapy, 2008, 9, 1087-1108.	0.9	61
96	Assessment of Sympathetic Cardiovascular Drive in Human Hypertension. Hypertension, 2009, 54, 690-697.	1.3	316
97	Heart Rate as a Risk Factor for Cardiovascular Disease. Progress in Cardiovascular Diseases, 2009, 52, 6-10.	1.6	169
98	Kidney Damage in Metabolic Syndrome: Nip It in the Bud. American Journal of Kidney Diseases, 2009, 53, 726-729.	2.1	10
99	Exercise therapy in Type 2 diabetes. Acta Diabetologica, 2009, 46, 263-278.	1.2	101
100	Treatment of hypertension in children and adolescents. Pediatric Nephrology, 2009, 24, 1939-1949.	0.9	38
101	Epidemiologic and pathophysiologic links between obesity and hypertension. Current Cardiovascular Risk Reports, 2009, 3, 264-271.	0.8	2
102	Elevated resting heart rate is associated with the metabolic syndrome. Cardiovascular Diabetology, 2009, 8, 55.	2.7	55
103	Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of γâ€melanocyteâ€stimulating hormone. Experimental Physiology, 2009, 94, 867-876.	0.9	2
104	Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. International Journal of Urology, 2009, 16, 493-498.	0.5	13
105	Central sympathetic overactivity: Maladies and mechanisms. Autonomic Neuroscience: Basic and Clinical, 2009, 148, 5-15.	1.4	153
106	Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 469-475.	1.1	19
107	Is obesity associated with lower body temperatures? Core temperature: a forgotten variable in energy balance. Metabolism: Clinical and Experimental, 2009, 58, 871-876.	1.5	60
108	Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. Metabolism: Clinical and Experimental, 2009, 58, 1446-1451.	1.5	19
109	The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America, 2009, 93, 569-582.	1.1	144
110	Obesity and Chronic Kidney Disease. Seminars in Nephrology, 2009, 29, 504-511.	0.6	18
111	Management of pediatric hypertension. Therapy: Open Access in Clinical Medicine, 2009, 6, 51-63.	0.2	2

#	Article	IF	CITATIONS
112	Differential effects of insulin on sympathetic nerve activity in agouti obese mice. Journal of Hypertension, 2010, 28, 1913-1919.	0.3	30
113	High-fat diet results in postprandial insulin resistance that involves parasympathetic dysfunction. British Journal of Nutrition, 2010, 104, 1450-1459.	1.2	18
114	Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. Journal of Physiology, 2010, 588, 3593-3603.	1.3	87
115	Socioâ€economic differentials in peripheral biology: Cumulative allostatic load. Annals of the New York Academy of Sciences, 2010, 1186, 223-239.	1.8	465
116	Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. American Journal of Clinical Nutrition, 2010, 92, 77-82.	2.2	104
117	Systemic energy homeostasis in Huntington's disease patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1233-1237.	0.9	47
118	Roles of Beta2- and Beta3-Adrenoceptor Polymorphisms in Hypertension and Metabolic Syndrome. International Journal of Hypertension, 2010, 2010, 1-12.	0.5	23
119	Metabolic Syndrome and Short-Term and Long-Term Heart Rate Variability in Elderly Free of Clinical Cardiovascular Disease: The PROOF Study. Rejuvenation Research, 2010, 13, 653-663.	0.9	68
120	Sympathetic Neural Activity in Hypertension and Related Diseases. American Journal of Hypertension, 2010, 23, 1052-1060.	1.0	203
121	Pregnancy and the endocrine regulation of the baroreceptor reflex. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R439-R451.	0.9	48
122	The Effect of Nutrition on Blood Pressure. Annual Review of Nutrition, 2010, 30, 365-401.	4.3	173
123	Sympathetic Nervous System Overactivity and Its Role in the Development of Cardiovascular Disease. Physiological Reviews, 2010, 90, 513-557.	13.1	578
124	The Effects of High Dietary Lard on Hypertension Development in Spontaneously Hypertensive Rats. Journal of Medicinal Food, 2010, 13, 1263-1272.	0.8	3
125	Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertension Research, 2011, 34, 407-412.	1.5	91
126	Overview of Endocrine Systems in Primary Hypertension. Endocrinology and Metabolism Clinics of North America, 2011, 40, 265-277.	1.2	6
127	The Effect of Obesity on Chronic Kidney Disease. , 2011, 21, 66-71.		49
128	Relationships of Adrenoceptor Polymorphisms with Obesity. Journal of Obesity, 2011, 2011, 1-10.	1.1	36
129	Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome. Frontiers in Physiology, 2011, 2, 52.	1.3	28

#	Article	IF	CITATIONS
130	Arcuate nucleus – a gateway for insulin's action on sympathetic activity. Journal of Physiology, 2011, 589, 2109-2110.	1.3	37
131	Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat–fed rats. Metabolism: Clinical and Experimental, 2011, 60, 1122-1130.	1.5	90
132	Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovascular Diabetology, 2011, 10, 24.	2.7	47
133	Effect of Weight Gain on Cardiac Autonomic Control During Wakefulness and Sleep. Hypertension, 2011, 57, 723-730.	1.3	23
134	Sympathetic Response to Insulin Is Mediated by Melanocortin 3/4 Receptors in the Hypothalamic Paraventricular Nucleus. Hypertension, 2011, 57, 435-441.	1.3	109
135	Visceral adiposity, not abdominal subcutaneous fat area, is associated with high blood pressure in Japanese men: the Ohtori study. Hypertension Research, 2011, 34, 565-572.	1.5	29
136	Oxidative stress in the brain causes hypertension via sympathoexcitation. Frontiers in Physiology, 2012, 3, 335.	1.3	49
137	Influence of High Glycemic Index and Glycemic Load Diets on Blood Pressure During Adolescence. Hypertension, 2012, 59, 1272-1277.	1.3	29
138	Different mechanisms in weight loss-induced blood pressure reduction between a calorie-restricted diet and exercise. Hypertension Research, 2012, 35, 41-47.	1.5	31
139	Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Journal of Hypertension, 2012, 30, 1992-1999.	0.3	42
140	Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. Journal of Hypertension, 2012, 30, 1646-1655.	0.3	36
141	High-fat diet-induced reduction of peroxisome proliferator–activated receptor-l̂³ coactivator-1l̂± messenger RNA levels and oxidative capacity in the soleus muscle of rats with metabolic syndrome. Nutrition Research, 2012, 32, 144-151.	1.3	21
142	Failure to increase postprandial blood flow in subcutaneous adipose tissue is associated with tissue resistance to adrenergic stimulation. Diabetes and Metabolism, 2012, 38, 27-33.	1.4	16
143	Core temperature: a forgotten variable in energy expenditure and obesity?. Obesity Reviews, 2012, 13, 97-104.	3.1	53
144	Cardiovascular and Renal Complications in Obesity and Obesity-Related Medical Conditions: Role of Sympathetic Nervous Activity and Insulin Resistance. , 2012, , .		0
145	Obesity-Associated Hypertension. , 2012, , 359-361.		1
146	The sympathetic nervous system and blood pressure in humans: implications for hypertension. Journal of Human Hypertension, 2012, 26, 463-475.	1.0	213
147	The effects of running exercise on oxidative capacity and PGC-11̂± mRNA levels in the soleus muscle of rats with metabolic syndrome. Journal of Physiological Sciences, 2012, 62, 105-114.	0.9	27

#	Article	IF	CITATIONS
148	Body Weight Loss by Very-Low-Calorie Diet Program Improves Small Artery Reactive Hyperemia in Severely Obese Patients. Obesity Surgery, 2013, 23, 17-23.	1.1	13
149	Understanding the Metabolic Syndrome: A Modeling Perspective. IEEE Reviews in Biomedical Engineering, 2013, 6, 143-155.	13.1	18
150	Sympathetic support of energy expenditure and sympathetic nervous system activity after gastric bypass surgery. Obesity, 2013, 21, 480-485.	1.5	29
151	Prevalence and determinants of metabolically healthy obesity in Spain. Atherosclerosis, 2013, 231, 152-157.	0.4	51
152	Obesityâ€Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment. Journal of Clinical Hypertension, 2013, 15, 14-33.	1.0	344
153	Differential patterns of regional neuroadrenergic cardiovascular drive in acromegalic disease. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 333-337.	0.9	2
154	Arcuate nucleus injection of an anti-insulin affibody prevents the sympathetic response to insulin. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1538-H1546.	1.5	40
155	Nutrition and Blood Pressure. , 2013, , 415-443.		0
156	Sympathoexcitation Associated with Renin-Angiotensin System in Metabolic Syndrome. International Journal of Hypertension, 2013, 2013, 1-7.	0.5	21
157	Influence of Feeding and Intracoronary Dose on Insulinâ€Mediated Relative Akt Phosphorylation in the Porcine Myocardium. Cardiovascular Therapeutics, 2013, 31, e125-32.	1.1	2
158	Obesityâ€related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the <i>The Obesity Society</i> and the <i>American Society of Hypertension</i> . Obesity, 2013, 21, 8-24.	1.5	203
159	MÃ <sub>i</sub> s allÃ <sub>i</sub> del sodio: cambios en la dieta y su efecto en hipertensión. Revista Chilena De CardiologÃ <b>a</b> , 2013, 32, 141-151.	0.0	1
160	Pathophysiology of Hypertension. , 2014, , 1-54.		0
161	Carotid body, insulin, and metabolic diseases: unraveling the links. Frontiers in Physiology, 2014, 5, 418.	1.3	67
162	Molecular basis of brain-mediated regulation of hepatic glucose metabolism. Diabetology International, 2014, 5, 158-164.	0.7	0
163	Influence of acute hyperlipidemia to adipocyte-derived hormones in lean normotensive and subjects with metabolic syndrome. Diabetology and Metabolic Syndrome, 2014, 6, 132.	1.2	3
164	Determinants of systolic blood pressure response during exercise in overweight subjects. Blood Pressure, 2014, 23, 200-205.	0.7	6
165	Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation. Journal of Physiology, 2014, 592, 1655-1675.	1.3	33

#	Article	IF	CITATIONS
167	Role of the Sympathetic Nervous System in Hypertension and Hypertension-Related Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 89-105.	1.0	40
168	Quiet standing after carbohydrate ingestion induces sympathoexcitatory and pressor responses in young healthy males. Autonomic Neuroscience: Basic and Clinical, 2014, 185, 112-119.	1.4	9
169	Type 2 Diabetes Mellitus and Hypertension. Endocrinology and Metabolism Clinics of North America, 2014, 43, 103-122.	1.2	231
170	Renal Denervation. Medicine (United States), 2015, 94, e1932.	0.4	11
171	Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Journal of Diabetes Research, 2015, 2015, 1-11.	1.0	273
173	Renal denervation for resistant hypertension. Revista Portuguesa De Cardiologia, 2015, 34, 125-135.	0.2	7
174	Renal denervation for resistant hypertension. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 125-135.	0.2	5
175	Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocrine Reviews, 2015, 36, 487-525.	8.9	649
176	Diets Higher in Protein Predict Lower High Blood Pressure Risk in Framingham Offspring Study Adults. American Journal of Hypertension, 2015, 28, 372-379.	1.0	27
177	Central Sympathetic Modulation Reverses Microvascular Alterations in a Rat Model of Highâ€Fat Dietâ€Induced Metabolic Syndrome. Microcirculation, 2016, 23, 320-329.	1.0	8
178	Temporal Relationship Between Childhood Body Mass Index and Insulin and Its Impact on Adult Hypertension. Hypertension, 2016, 68, 818-823.	1.3	42
179	Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy. BMC Pharmacology & amp; Toxicology, 2016, 17, 9.	1.0	7
180	Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward. Atherosclerosis, 2016, 247, 225-282.	0.4	67
181	Impact of Adiposity on Incident Hypertension Is Modified by Insulin Resistance in Adults. Hypertension, 2016, 67, 56-62.	1.3	36
182	The Association of Pediatric Obesity With Nocturnal Non-Dipping on 24-Hour Ambulatory Blood Pressure Monitoring. American Journal of Hypertension, 2016, 29, 647-652.	1.0	53
183	Metabolically healthy obesity and health-related quality of life: A prospective cohort study. Clinical Nutrition, 2017, 36, 853-860.	2.3	21
184	Nutritional Interventions to Lower Cholesterol and Risk for Heart Disease in Children. , 2017, , 229-249.		0
185	The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017. 312. R965-R972.	0.9	9

#	Article	IF	CITATIONS
186	Glycemic index, glycemic load, and metabolic syndrome in Mexican adolescents: a cross-sectional study from the NHNS-2012. BMC Nutrition, 2017, 3, 44.	0.6	5
187	The Role of the Autonomic Nervous System in the Pathophysiology of Obesity. Frontiers in Physiology, 2017, 8, 665.	1.3	160
188	Higher body mass index predicts cardiac autonomic dysfunction: A longitudinal study in adolescent type 1 diabetes. Pediatric Diabetes, 2018, 19, 794-800.	1.2	26
189	Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. Journal of Hypertension, 2018, 36, 1195-1200.	0.3	6
190	Effects of Multi-Electrode Renal Denervation on Insulin Sensitivity and Glucose Metabolism in a Canine Model of Type 2 Diabetes Mellitus. Journal of Vascular and Interventional Radiology, 2018, 29, 731-738.e2.	0.2	12
191	Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgraduate Medicine, 2018, 130, 325-333.	0.9	52
192	Comparison of ambulatory blood pressure monitoring and office blood pressure measurements in obese children and adolescents. Acta Clinica Belgica, 2018, 73, 126-131.	0.5	6
193	Chronic renal artery insulin infusion increases mean arterial pressure in male Sprague-Dawley rats. American Journal of Physiology - Renal Physiology, 2018, 314, F81-F88.	1.3	11
194	Improved glucose homeostasis in male obese Zucker rats coincides with enhanced baroreflexes and activation of the nucleus tractus solitarius. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2018, 315, R1195-R1209.	0.9	8
196	A Review on the Protective Effects of Honey against Metabolic Syndrome. Nutrients, 2018, 10, 1009.	1.7	43
197	Temporal relationship between body mass index and triglyceride-glucose index and its impact on the incident ofÂhypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1220-1229.	1.1	29
198	Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. Hypertension, 2019, 74, 903-909.	1.3	13
199	Cardiovascular autonomic reflex tests and serum FGF21 levels in overweight and normal-weight men and women. Archives of Physiology and Biochemistry, 2019, , 1-5.	1.0	2
200	Tissue sodium content in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2019, 33, 485-489.	1.2	24
201	Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Wholeâ€Body Imaging: UK Biobank and Oxford BioBank. Obesity, 2019, 27, 1200-1206.	1.5	38
202	Sympathetic Denervation of the Common Hepatic Artery Lessens Glucose Intolerance in the Fat- and Fructose-Fed Dog. Diabetes, 2019, 68, 1143-1155.	0.3	20
203	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. Cardiovascular Diabetology, 2019, 18, 160.	2.7	14
204	Baroreflex activation therapy systems: current status and future prospects. Expert Review of Medical Devices, 2019, 16, 1025-1033.	1.4	14

#	Article	IF	CITATIONS
205	Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload. Hypertension, 2020, 76, 1444-1450.	1.3	16
206	An overview of the health benefits of Prunus species with special reference to metabolic syndrome risk factors. Food and Chemical Toxicology, 2020, 144, 111574.	1.8	16
207	Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. Journal of Hypertension, 2020, 38, 1436-1442.	0.3	26
208	Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance. Acta Diabetologica, 2020, 57, 1227-1243.	1.2	24
209	Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies. Journal of Hypertension, 2020, 38, 565-572.	0.3	20
210	The Effects of Salt and Glucose Intake on Angiotensin II and Aldosterone in Obese and Nonobese Patients with Essential Hypertension. International Journal of Hypertension, 2020, 2020, 1-9.	0.5	5
211	The effect of gum consumption on blood pressure as a risk factor for coronary heart disease: A meta-analysis of controlled trials. International Journal for Vitamin and Nutrition Research, 2021, , 1-11.	0.6	0
212	Direct and Indirect Effect of Honey as a Functional Food Against Metabolic Syndrome and Its Skeletal Complications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 241-256.	1.1	12
213	Autonomic Nervous System in Obesity and Insulin-Resistance—The Complex Interplay between Leptin and Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 5187.	1.8	36
214	Adipose Tissue and Biological Factors. Possible Link between Lymphatic System Dysfunction and Obesity. Metabolites, 2021, 11, 617.	1.3	11
215	Metabolic Score for Visceral Fat: A reliable indicator of visceral obesity for predicting risk for hypertension. Nutrition, 2022, 93, 111443.	1.1	12
216	The Sympatho-Adrenal System in the Metabolic Syndrome. , 2008, , 85-104.		3
217	Cardiovascular Regulation: Basic Considerations. , 2007, , 1525-1539.		7
218	Pathophysiology of Hypertension. , 2009, , 1485-1518.		10
219	Neuroendocrine Stress Response and Its Impact on Eating Behavior and Body Weight. , 2010, , 261-271.		3
220	Diabetes Mellitus and Metabolic Syndrome. , 2009, , 465-496.		5
221	Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. Journal of Clinical Investigation, 2004, 114, 652-658.	3.9	162
222	Cardiac magnetic resonance assessment of aortic distensibility in prediabetic patients. Egyptian Heart Journal, 2020, 72, 4.	0.4	2

	CITATION	KEPORI	
#	Article	IF	CITATIONS
223	Cerebral Blood Flow Links Insulin Resistance and Baroreflex Sensitivity. PLoS ONE, 2013, 8, e83288.	1.1	18
224	Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women. Recent Patents on Anti-Cancer Drug Discovery, 2013, 8, 154-167.	0.8	37
225	The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Korean Journal of Internal Medicine, 2020, 35, 1385-1399.	0.7	10
226	Metabolic Syndrome: Definition and Pathophysiology and #8211; the discussion goes on!. Journal of Physiology and Pharmacology Advances, 2013, 3, 48.	0.1	18
227	The Epithelial Sodium Channel. , 2007, , 45-84.		0
228	Resolución de las patologÃas comórbidas bariátricas. , 2009, , 371-376.		0
229	Effects of aerobic exercise intensity on insulin resistance, renin-angiotensin â…; and C-reactive protein in patients with metabolic syndrome. Exercise Science, 2009, 18, 443-454.	0.1	5
230	The phenotypic patterns of essential hypertension are the key to identifying "high blood pressure― genes Physiological Research, 2010, 59, 841-857.	0.4	8
231	Hypertension in Children with the Metabolic Syndrome or Type 2 Diabetes. , 2011, , 329-342.		0
232	Regulation of glucose metabolism by central insulin action. Biomedical Reviews, 2014, 22, 31.	0.6	1
235	Hypertension in Children with the Metabolic Syndrome or Type 2 Diabetes. , 2013, , 279-294.		0
236	Eggs Effects on HDL-C Metabolism, Inammation, and Insulin Resistance. , 2015, , 332-345.		0
237	Pathophysiology of Pediatric Hypertension. , 2016, , 1951-1995.		0
238	Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome. , 2017, , 1-19.		0
239	Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome. , 2018, , 385-403.		0
240	Effects of Lifestyle on Urinary Health. , 2019, , 27-40.		0
241	Nutrition and blood pressure. , 2022, , 699-739.		0
242	The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?. Biomolecules, 2021, 11, 1652.	1.8	6

#	Article	IF	CITATIONS
243	Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study. American Journal of Cardiovascular Disease, 2011, 1, 48-59.	0.5	26
244	Abnormal cation exchange in insulin-resistant patients with essential hypertension. Cardiovascular Journal of Africa, 2008, 19, 67-71.	0.2	0
245	Role of the Autonomic Nervous System in Mechanism of Energy and Glucose Regulation Post Bariatric Surgery. Frontiers in Neuroscience, 2021, 15, 770690.	1.4	5
246	Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms, 2021, 9, 2351.	1.6	21
247	Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study. Endocrines, 2022, 3, 43-52.	0.4	2
250	Pregnancy restores altered sympathetic vasomotor modulation and parasympathetic cardiac modulation in hypertensive rats. Pregnancy Hypertension, 2022, 28, 180-188.	0.6	2
251	The hypothalamic-pituitary-adrenal axis and the central monoaminergic systems: a pathophysiological link to insomnia with clinical implications. Sleep Science, 2022, 15, 128-135.	0.4	3
253	Metabolic associated fatty liver disease is a disease related to sympathetic nervous system activation. World Chinese Journal of Digestology, 2022, 30, 465-476.	0.0	0
256	Association of general and abdominal adiposity with postural changes in systolic blood pressure: results from the NAKO pretest and MetScan studies. Hypertension Research, 0, , .	1.5	1
257	Association of cardio-metabolic risk factors with elevated basal heart rate in South African Asian Indians. Minerva Endocrinology, 2022, 47, .	0.6	0
258	Association of triglyceride–glucose index and its 6-year change with risk of hypertension: A prospective cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 568-576.	1.1	6
259	Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome. , 2023, , 421-437.		0
260	Diabetes and Sympathetic Nervous System. Updates in Hypertension and Cardiovascular Protection, 2023, , 153-165.	0.1	0
261	Participation of Leptin and Corticosterone in the Decrease in Infarct-Limiting Efficiency of Remote Postconditioning and in the Development of Arterial Hypertension in Metabolic Syndrome in Rats. Bulletin of Experimental Biology and Medicine, 2023, 174, 312-317.	0.3	2
262	Associations of the Triglyceride and Glucose Index With Hypertension Stages, Phenotypes, and Their Progressions Among Middle-Aged and Older Chinese. International Journal of Public Health, 0, 68, .	1.0	3